>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
黄芪甲苷的抗氧化性对缺氧缺糖 H9c2细胞的保护作用探讨
作者:承燕  吕磊  江时森 
单位:南京大学医学院临床学院,南京军区南京总医院 心内科,江苏 南京 210002
关键词:黄芪甲苷 H9c2细胞 缺氧 自由基 
分类号:R-33; R285.5
出版年·卷·期(页码):2012·31·第一期(51-55)
摘要:

目的:探讨黄芪甲苷(AST-Ⅳ)的抗氧化性对缺氧缺糖H9c2细胞的保护作用。方法:对用无糖Na2S2O4溶液制造的细胞缺氧模型给予AST-Ⅳ预处理,同时以抗氧化能力相近的抗氧化剂水溶性维生素E(Trolox)作为对照检测细胞内氧自由基(ROS)、丙二醛(MDA)的浓度和乳酸脱氢酶(LDH)漏出率,CCK-8检测细胞存活率,FITC-annexin V/PI双染检测凋亡情况。结果:经60 μmol·L-1的AST-Ⅳ预处理后,细胞内ROS、MDA浓度较模型组有明显下降(P<0.01),下降程度与Trolox预处理组相近。AST-Ⅳ预处理组细胞存活率明显高于模型组(P<0.01),但低于Trolox预处理组(P<0.01)。AST-Ⅳ预处理组LDH漏出率和细胞凋亡率较模型组均下降(P<0.01),但不如Trolox预处理组下降明显(P<0.01)。结论:AST-Ⅳ能减轻无糖Na2S2O4溶液造成的细胞氧化应激,但效果不如Trolox,其抗氧化性对H9c2细胞的保护作用有限。

Objective: To investigate the protection effect of antioxidant activity of astragaloside Ⅳ(AST-Ⅳ) on H9c2 cells injured by hypoxia. Methods: AST-Ⅳ was administrated an hour before oxygen and glucose deprivation, and the levels of intracellular ROS and malondialdehyde(MDA), cell viability, apoptosis and necrosis were measured and were compared with Trolox which had an equal antioxidant capacity. Cell viability was determined by a CCK-8 kit. Cell necrosis was assayed by the ratio of released LDH. FITC-annexin V/PI was used for apoptosis. Results: The intracellular ROS and MDA formation after 60 μmol·L-1 AST-Ⅳ pretreatment decreased as low as after Trolox pretreatment. The cell viability, ratio of released LDH and apoptosis were ameliorated in AST-Ⅳ pretreatment group compared to hypoxia group(P<0.01). However, Tolox pretreatment improved those indexes better than AST-Ⅳ pretreatment(P<0.01). Conclusion: AST-Ⅳ reduces the oxidative stress in H9c2 cells injured by oxygen and glucose deprivation, while it is less effective than Trolox. The antioxidant properties of AST-Ⅳ has limitations in protective effect.

参考文献:

[1] HU J Y,HAN J,CHU Z G,et al.Astragaloside Ⅳ attenuates hypoxia-induced cardiomyocyte damage in rats by upregulating superoxide dismutase-1 levels[J].Clin Exp Pharmacol Physiol,2009,36(4):351-357.
[2] 关凤英,李红,杨世杰.黄芪甲苷诱导NO生成并激活PKCε对大鼠心肌缺血再灌注损伤的保护作用[J].吉林大学学报:医学版,2010,36(2):340-344.
[3] ZHANG W D,CHEN H,ZHANG C,et al.Astragaloside Ⅳ from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro[J].Planta Med,2006,72(1):4-8.
[4] 胡炯宇,黄跃生,张琼,等.黄芪甲苷减轻缺氧心肌细胞氧化损伤的机制研究[J].中国烧伤杂志,2007,23(3):175-178.
[5] LI Z P,CAO Q.Effects of astragaloside Ⅳ on myocardial calcium transport and cardiac function in ischemic rats[J].Acta Pharmacol Sin,2002,23(10):898-904.
[6] XU X L,CHEN X J,JI H,et al.Astragaloside Ⅳ improved intracellular calcium handling in hypoxia-reoxygenated cardiomyocytes via the sarcoplasmic reticulum Ca-ATPase[J].Pharmacology,2008,81(4):325-332.
[7] 夏之宁,庞媛,郑国灿.基于毛细管电泳的黄芪抗氧化生物指纹图谱研究[J].分析化学,2008,36(12):1646-1650.
[8] 承燕,江时森.黄芪甲苷对心血管保护功能的研究进展[J].医学研究生学报,2011,24(6):637-640.
[9] 杨国富,刘革新,董果雄,等.黄芪甲苷对缺氧/复氧损伤人脐静脉内皮细胞与中性粒细胞黏附能力及细胞核转录因子κb表达的影响[J].中国组织工程研究与临床康复,2008,12(15):2843-2846.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 250585 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364